sar425899 dual agonist glp-1 glucagon sanofi Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes - Cheang - 2018 Effects on weight loss and

Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome

doi: 10.1186/s12929-017-0379-z 68 CardosoSCarvalhoCCorreiaSCSeicaRMMoreiraPI

The most common reasons are documentation deficiencies (missing BMI or comorbidity records), step therapy requirements (you haven't tried a required prior medication), structural coverage exclusion (your plan doesn't cover GLP-1s for obesity), or indication mismatch (you were prescribed Ozempic for weight loss when only Wegovy is approved for that use)

Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine , vol